ALC Stock Forecast & Price Target

Alcon is favorably positioned because it is the pure-play leader in ophthalmic medical devices, with a broad two-segment franchise in Vision Care and Surgical that combines market-leading contact lens brands, ocular health products, implantables, and equipment with one of the world’s largest installed bases of eye surgical systems. Its growth outlook is being driven by multiple new products and share gains—evidenced by about 7% xFx growth in 2Q26, Core EPS of $0.84, gross margin and operating margin beats of +340bps and +190bps, and FY26 guidance for 5%-7% xFx revenue growth, 20.7%-21.7% Core operating margins, and 12%-15% xFx Core EPS growth—while Unity, PanOptix Pro, Vivity Pro, and Valeda provide additional catalysts across Surgical and Vision Care. Despite tariff and competitive pressures, the company’s expanding margins, improving free cash flow, and ability to offset softer end markets with innovation and operating leverage support the view that it can sustain above-market growth and deliver double-digit EPS expansion.

Alcon is facing a fundamentally mixed setup in which reported growth is being supported by price increases, product launches, and foreign exchange rather than broad-based underlying demand, while core end markets remain only in the 3% to 4% growth range and cataract conditions are described as soft. The Surgical franchise, despite generating $1.460B in 1Q26 and $1.570B in 2Q26, continues to show competitive pressure in implantables, lower sales in surgical glaucoma, and vulnerability to tariffs, including a $40M to $90M net headwind in FY26, while the $402M PowerVision write-off underscores execution and capital-allocation risk. Although Vision Care is benefiting from Tryptyr, Precision7, and stronger US share, the gains are still early and partially offset by unfavorable gross-to-net adjustments, legacy product declines, and rising operating expenses, leaving margin expansion and FY26 core EPS growth of 12% to 15% dependent on conditions that appear increasingly fragile.